Joel Stephen Finkelstein, M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Bone Density | 68 | 2022 | 3395 | 5.630 |
Why?
|
| Osteoporosis | 38 | 2022 | 1556 | 3.580 |
Why?
|
| Menopause | 21 | 2023 | 1518 | 2.720 |
Why?
|
| Teriparatide | 11 | 2014 | 230 | 2.510 |
Why?
|
| Testosterone | 33 | 2020 | 2352 | 2.170 |
Why?
|
| Absorptiometry, Photon | 26 | 2022 | 1692 | 2.140 |
Why?
|
| Osteoporosis, Postmenopausal | 11 | 2016 | 394 | 1.960 |
Why?
|
| Cystic Fibrosis | 7 | 2022 | 1156 | 1.870 |
Why?
|
| Radius | 12 | 2021 | 397 | 1.840 |
Why?
|
| Goserelin | 6 | 2020 | 128 | 1.830 |
Why?
|
| Libido | 4 | 2020 | 117 | 1.770 |
Why?
|
| Estradiol | 23 | 2019 | 1974 | 1.720 |
Why?
|
| Anti-Mullerian Hormone | 3 | 2023 | 382 | 1.620 |
Why?
|
| Fractures, Bone | 15 | 2022 | 1849 | 1.540 |
Why?
|
| Bone Density Conservation Agents | 11 | 2022 | 789 | 1.510 |
Why?
|
| Tibia | 7 | 2018 | 1028 | 1.310 |
Why?
|
| Body Composition | 13 | 2022 | 2393 | 1.190 |
Why?
|
| Bone and Bones | 11 | 2021 | 2567 | 1.170 |
Why?
|
| Bone Diseases, Metabolic | 6 | 2022 | 398 | 1.160 |
Why?
|
| Fragile X Mental Retardation Protein | 2 | 2016 | 108 | 1.160 |
Why?
|
| Leuprolide | 7 | 2017 | 309 | 1.080 |
Why?
|
| Androstenedione | 5 | 2002 | 130 | 1.080 |
Why?
|
| Gonadotropin-Releasing Hormone | 17 | 2017 | 1188 | 1.040 |
Why?
|
| Women's Health | 17 | 2022 | 1898 | 0.980 |
Why?
|
| Alendronate | 5 | 2010 | 175 | 0.960 |
Why?
|
| Lumbar Vertebrae | 19 | 2022 | 1817 | 0.960 |
Why?
|
| Asian Americans | 3 | 2016 | 699 | 0.930 |
Why?
|
| Bone Remodeling | 11 | 2018 | 592 | 0.910 |
Why?
|
| Aminophenols | 1 | 2021 | 74 | 0.820 |
Why?
|
| Menstrual Cycle | 5 | 2020 | 531 | 0.820 |
Why?
|
| African Americans | 9 | 2017 | 5118 | 0.770 |
Why?
|
| Vitamin D | 9 | 2019 | 3138 | 0.760 |
Why?
|
| Muscle Strength | 2 | 2013 | 570 | 0.750 |
Why?
|
| Hypogonadism | 14 | 2016 | 753 | 0.740 |
Why?
|
| Anabolic Agents | 3 | 2010 | 250 | 0.720 |
Why?
|
| Antineoplastic Agents, Hormonal | 8 | 2019 | 1521 | 0.700 |
Why?
|
| Premenopause | 10 | 2022 | 1009 | 0.660 |
Why?
|
| Quinolones | 1 | 2021 | 393 | 0.650 |
Why?
|
| Bone Resorption | 7 | 2013 | 746 | 0.610 |
Why?
|
| Parathyroid Hormone | 10 | 2012 | 1819 | 0.610 |
Why?
|
| Eunuchism | 1 | 2016 | 19 | 0.600 |
Why?
|
| Climacteric | 4 | 2004 | 57 | 0.590 |
Why?
|
| Perimenopause | 4 | 2017 | 131 | 0.590 |
Why?
|
| Reproduction | 2 | 2020 | 639 | 0.570 |
Why?
|
| Femur Neck | 9 | 2022 | 306 | 0.560 |
Why?
|
| Ergocalciferols | 2 | 2015 | 119 | 0.550 |
Why?
|
| Vitamin D Deficiency | 7 | 2019 | 1356 | 0.550 |
Why?
|
| Prescriptions | 2 | 2021 | 335 | 0.540 |
Why?
|
| Aromatase Inhibitors | 6 | 2019 | 503 | 0.530 |
Why?
|
| Postmenopause | 8 | 2021 | 2405 | 0.520 |
Why?
|
| Middle Aged | 95 | 2022 | 213752 | 0.520 |
Why?
|
| Follicle Stimulating Hormone, Human | 1 | 2013 | 24 | 0.500 |
Why?
|
| Histamine H2 Antagonists | 1 | 2015 | 169 | 0.500 |
Why?
|
| Hormones | 7 | 2017 | 855 | 0.480 |
Why?
|
| Fibroblast Growth Factors | 2 | 2012 | 878 | 0.480 |
Why?
|
| Adult | 94 | 2022 | 211041 | 0.470 |
Why?
|
| Nafarelin | 4 | 1999 | 27 | 0.460 |
Why?
|
| Bone Cements | 4 | 2006 | 326 | 0.430 |
Why?
|
| Female | 107 | 2023 | 375205 | 0.430 |
Why?
|
| Obesity, Morbid | 3 | 2018 | 1066 | 0.430 |
Why?
|
| Spinal Neoplasms | 6 | 2015 | 837 | 0.420 |
Why?
|
| Adipose Tissue | 4 | 2022 | 3234 | 0.420 |
Why?
|
| Puberty, Delayed | 3 | 1999 | 114 | 0.420 |
Why?
|
| Adiposity | 2 | 2020 | 1734 | 0.420 |
Why?
|
| Menstruation | 5 | 2020 | 288 | 0.420 |
Why?
|
| Gastric Bypass | 2 | 2018 | 727 | 0.410 |
Why?
|
| Humans | 160 | 2023 | 708843 | 0.410 |
Why?
|
| Gonadotropins | 6 | 1991 | 237 | 0.410 |
Why?
|
| Spinal Fractures | 7 | 2011 | 688 | 0.410 |
Why?
|
| Natriuretic Peptide, Brain | 1 | 2019 | 1574 | 0.400 |
Why?
|
| Polymethyl Methacrylate | 3 | 2006 | 132 | 0.400 |
Why?
|
| Infertility, Female | 1 | 2016 | 752 | 0.400 |
Why?
|
| Spinal Cord Compression | 2 | 2015 | 223 | 0.390 |
Why?
|
| Proton Pump Inhibitors | 1 | 2015 | 468 | 0.390 |
Why?
|
| Fractures, Spontaneous | 9 | 2011 | 240 | 0.390 |
Why?
|
| Follicle Stimulating Hormone | 16 | 2019 | 731 | 0.390 |
Why?
|
| Drug Utilization | 2 | 2016 | 1223 | 0.380 |
Why?
|
| Prostatic Neoplasms | 11 | 2011 | 10525 | 0.380 |
Why?
|
| Antihypertensive Agents | 2 | 2019 | 2046 | 0.370 |
Why?
|
| Longitudinal Studies | 23 | 2020 | 13536 | 0.360 |
Why?
|
| Phosphates | 3 | 2012 | 787 | 0.360 |
Why?
|
| Cohort Studies | 29 | 2021 | 39292 | 0.360 |
Why?
|
| Estrogens | 5 | 2017 | 1511 | 0.360 |
Why?
|
| Prescription Drugs | 1 | 2016 | 607 | 0.350 |
Why?
|
| Tomography, X-Ray Computed | 15 | 2018 | 20308 | 0.350 |
Why?
|
| Male | 95 | 2022 | 349524 | 0.350 |
Why?
|
| Orthopedic Procedures | 3 | 2008 | 1278 | 0.330 |
Why?
|
| Peptide Fragments | 3 | 2019 | 5141 | 0.330 |
Why?
|
| Osteocalcin | 7 | 2012 | 277 | 0.330 |
Why?
|
| Decompression, Surgical | 2 | 2014 | 588 | 0.330 |
Why?
|
| Injections, Subcutaneous | 4 | 2020 | 685 | 0.320 |
Why?
|
| Gonadal Steroid Hormones | 9 | 2014 | 688 | 0.320 |
Why?
|
| Osteoporotic Fractures | 2 | 2022 | 370 | 0.310 |
Why?
|
| Spinal Osteophytosis | 1 | 2006 | 29 | 0.310 |
Why?
|
| Spinal Canal | 1 | 2006 | 41 | 0.310 |
Why?
|
| Androgens | 5 | 2019 | 1216 | 0.310 |
Why?
|
| Dietary Supplements | 6 | 2019 | 3025 | 0.310 |
Why?
|
| Spine | 9 | 2018 | 1102 | 0.310 |
Why?
|
| Selective Estrogen Receptor Modulators | 2 | 2017 | 130 | 0.290 |
Why?
|
| Spinal Fusion | 3 | 2014 | 1175 | 0.290 |
Why?
|
| Health Behavior | 2 | 2016 | 2576 | 0.290 |
Why?
|
| Nitriles | 3 | 2005 | 950 | 0.280 |
Why?
|
| Trinucleotide Repeats | 2 | 2016 | 270 | 0.280 |
Why?
|
| Laminectomy | 1 | 2006 | 236 | 0.280 |
Why?
|
| Aging | 5 | 2020 | 8358 | 0.280 |
Why?
|
| Pain, Intractable | 1 | 2006 | 130 | 0.270 |
Why?
|
| Aged | 49 | 2021 | 161488 | 0.270 |
Why?
|
| Bone Development | 5 | 2005 | 484 | 0.270 |
Why?
|
| Bariatric Surgery | 1 | 2014 | 871 | 0.270 |
Why?
|
| Patient Compliance | 6 | 2017 | 2758 | 0.260 |
Why?
|
| Dose-Response Relationship, Drug | 11 | 2020 | 11239 | 0.260 |
Why?
|
| Ovary | 3 | 2023 | 997 | 0.260 |
Why?
|
| Vitamins | 2 | 2012 | 1466 | 0.260 |
Why?
|
| Diphosphonates | 4 | 2007 | 616 | 0.250 |
Why?
|
| Follow-Up Studies | 15 | 2022 | 39038 | 0.250 |
Why?
|
| Case-Control Studies | 7 | 2022 | 21194 | 0.250 |
Why?
|
| Hypoglycemic Agents | 1 | 2016 | 2734 | 0.250 |
Why?
|
| Triazoles | 3 | 2014 | 910 | 0.240 |
Why?
|
| Spinal Diseases | 2 | 2008 | 557 | 0.240 |
Why?
|
| Insulin Resistance | 5 | 2022 | 3866 | 0.240 |
Why?
|
| Epitestosterone | 1 | 2002 | 3 | 0.240 |
Why?
|
| Endometriosis | 3 | 1999 | 773 | 0.230 |
Why?
|
| United States | 22 | 2021 | 67165 | 0.230 |
Why?
|
| Administration, Cutaneous | 2 | 2020 | 696 | 0.220 |
Why?
|
| Overweight | 1 | 2013 | 2205 | 0.220 |
Why?
|
| Aged, 80 and over | 24 | 2020 | 58184 | 0.220 |
Why?
|
| Estranes | 1 | 2000 | 3 | 0.210 |
Why?
|
| Collagen Type I | 6 | 2014 | 576 | 0.210 |
Why?
|
| Nandrolone | 1 | 2000 | 18 | 0.210 |
Why?
|
| Anilides | 1 | 2004 | 422 | 0.210 |
Why?
|
| Calcium | 5 | 2006 | 5825 | 0.210 |
Why?
|
| Penile Erection | 1 | 2020 | 93 | 0.200 |
Why?
|
| Bone Neoplasms | 5 | 2017 | 2579 | 0.190 |
Why?
|
| Prospective Studies | 12 | 2022 | 50597 | 0.190 |
Why?
|
| Cervical Vertebrae | 1 | 2006 | 958 | 0.190 |
Why?
|
| Nonprescription Drugs | 1 | 2000 | 116 | 0.190 |
Why?
|
| Drug Contamination | 1 | 2000 | 151 | 0.190 |
Why?
|
| Practice Guidelines as Topic | 4 | 2012 | 7487 | 0.190 |
Why?
|
| Young Adult | 12 | 2022 | 55940 | 0.190 |
Why?
|
| Luteinizing Hormone | 13 | 2017 | 871 | 0.190 |
Why?
|
| Gels | 1 | 2020 | 438 | 0.180 |
Why?
|
| Body Fat Distribution | 1 | 2020 | 242 | 0.180 |
Why?
|
| Chromatography, Liquid | 2 | 2014 | 959 | 0.180 |
Why?
|
| Treatment Outcome | 20 | 2020 | 61932 | 0.180 |
Why?
|
| Hip | 2 | 2021 | 253 | 0.170 |
Why?
|
| Body Mass Index | 9 | 2022 | 12366 | 0.170 |
Why?
|
| Mass Screening | 2 | 2012 | 5182 | 0.170 |
Why?
|
| Drug Therapy, Combination | 3 | 2020 | 6562 | 0.170 |
Why?
|
| Cystic Fibrosis Transmembrane Conductance Regulator | 1 | 2021 | 422 | 0.170 |
Why?
|
| Reference Values | 5 | 2016 | 5041 | 0.170 |
Why?
|
| Computer Simulation | 1 | 2012 | 6048 | 0.170 |
Why?
|
| Body Weight | 4 | 2019 | 4680 | 0.170 |
Why?
|
| Orthopedics | 3 | 2022 | 805 | 0.160 |
Why?
|
| Administration, Topical | 1 | 2019 | 700 | 0.160 |
Why?
|
| Prediabetic State | 1 | 2022 | 468 | 0.160 |
Why?
|
| Estrone | 4 | 2017 | 230 | 0.150 |
Why?
|
| Tandem Mass Spectrometry | 2 | 2014 | 1115 | 0.150 |
Why?
|
| Spinal Cord Injuries | 2 | 2015 | 991 | 0.150 |
Why?
|
| Blood Chemical Analysis | 2 | 2014 | 460 | 0.150 |
Why?
|
| Galactose | 1 | 2017 | 309 | 0.150 |
Why?
|
| Amino Acid Substitution | 1 | 2021 | 1823 | 0.150 |
Why?
|
| Sodium Chloride Symporter Inhibitors | 1 | 2015 | 79 | 0.140 |
Why?
|
| Receptors, Histamine H2 | 1 | 2015 | 19 | 0.140 |
Why?
|
| Immunoassay | 2 | 2012 | 766 | 0.140 |
Why?
|
| Patient Satisfaction | 1 | 2008 | 3376 | 0.140 |
Why?
|
| Cross-Sectional Studies | 9 | 2022 | 23020 | 0.140 |
Why?
|
| Eating | 1 | 2022 | 1443 | 0.140 |
Why?
|
| Pituitary Hormone-Releasing Hormones | 3 | 1990 | 43 | 0.140 |
Why?
|
| Femur | 3 | 2012 | 1274 | 0.140 |
Why?
|
| Calcitriol | 3 | 2006 | 307 | 0.140 |
Why?
|
| 24,25-Dihydroxyvitamin D 3 | 1 | 2014 | 9 | 0.130 |
Why?
|
| Time Factors | 11 | 2015 | 41038 | 0.130 |
Why?
|
| Collagen | 4 | 2013 | 2687 | 0.130 |
Why?
|
| Hormone Replacement Therapy | 2 | 2015 | 732 | 0.130 |
Why?
|
| Tibial Fractures | 1 | 2017 | 241 | 0.130 |
Why?
|
| Androgen Antagonists | 3 | 2011 | 1269 | 0.130 |
Why?
|
| Urinalysis | 3 | 2002 | 363 | 0.130 |
Why?
|
| Glycosylation | 1 | 2017 | 1127 | 0.120 |
Why?
|
| Reconstructive Surgical Procedures | 1 | 2006 | 2137 | 0.120 |
Why?
|
| Osteogenesis | 3 | 2014 | 1283 | 0.120 |
Why?
|
| Multivariate Analysis | 6 | 2014 | 12447 | 0.120 |
Why?
|
| Propensity Score | 2 | 2019 | 1715 | 0.120 |
Why?
|
| Drug Monitoring | 1 | 2019 | 936 | 0.120 |
Why?
|
| Spondylolisthesis | 1 | 2014 | 158 | 0.120 |
Why?
|
| Motor Activity | 3 | 2014 | 2749 | 0.110 |
Why?
|
| Patient Education as Topic | 3 | 2008 | 2340 | 0.110 |
Why?
|
| Drug Combinations | 2 | 2009 | 1925 | 0.110 |
Why?
|
| Sex Hormone-Binding Globulin | 6 | 2019 | 536 | 0.110 |
Why?
|
| Obesity | 2 | 2019 | 12031 | 0.110 |
Why?
|
| Peptides | 6 | 2014 | 4424 | 0.110 |
Why?
|
| Adolescent | 15 | 2022 | 84718 | 0.110 |
Why?
|
| Risk Factors | 13 | 2019 | 69553 | 0.110 |
Why?
|
| Finite Element Analysis | 1 | 2013 | 409 | 0.110 |
Why?
|
| Administration, Oral | 4 | 2002 | 3944 | 0.110 |
Why?
|
| Alkaline Phosphatase | 3 | 2003 | 892 | 0.110 |
Why?
|
| Antidepressive Agents, Tricyclic | 1 | 2013 | 441 | 0.110 |
Why?
|
| Mutation, Missense | 1 | 2021 | 2503 | 0.110 |
Why?
|
| Fertility | 1 | 2016 | 712 | 0.110 |
Why?
|
| Hypercalcemia | 1 | 2014 | 426 | 0.100 |
Why?
|
| Weight-Bearing | 1 | 2013 | 519 | 0.100 |
Why?
|
| Sex Factors | 6 | 2017 | 10566 | 0.100 |
Why?
|
| Japan | 2 | 2013 | 1320 | 0.100 |
Why?
|
| Prognosis | 4 | 2020 | 28919 | 0.100 |
Why?
|
| Polysaccharides | 1 | 2017 | 991 | 0.100 |
Why?
|
| Diet | 2 | 2006 | 7392 | 0.100 |
Why?
|
| Pituitary Gland | 4 | 1989 | 667 | 0.100 |
Why?
|
| Fractures, Compression | 1 | 2011 | 131 | 0.100 |
Why?
|
| Adrenergic beta-Antagonists | 1 | 2015 | 1224 | 0.090 |
Why?
|
| Age Factors | 7 | 2015 | 18712 | 0.090 |
Why?
|
| Logistic Models | 5 | 2019 | 13468 | 0.090 |
Why?
|
| Gene Frequency | 1 | 2016 | 3701 | 0.090 |
Why?
|
| Procollagen | 2 | 2006 | 191 | 0.090 |
Why?
|
| Risk | 3 | 2019 | 9641 | 0.090 |
Why?
|
| Embalming | 1 | 1988 | 12 | 0.090 |
Why?
|
| China | 2 | 2013 | 2251 | 0.090 |
Why?
|
| Substance Abuse Detection | 2 | 2002 | 288 | 0.090 |
Why?
|
| Blood Glucose | 4 | 2022 | 6255 | 0.090 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2015 | 1478 | 0.090 |
Why?
|
| Pelvic Bones | 2 | 2018 | 271 | 0.080 |
Why?
|
| Diabetes Mellitus, Type 2 | 3 | 2016 | 10857 | 0.080 |
Why?
|
| Odds Ratio | 2 | 2016 | 9754 | 0.080 |
Why?
|
| Health Knowledge, Attitudes, Practice | 3 | 2008 | 3934 | 0.080 |
Why?
|
| Gynecomastia | 1 | 1988 | 89 | 0.080 |
Why?
|
| Chorionic Gonadotropin | 1 | 1989 | 456 | 0.080 |
Why?
|
| Risk Assessment | 6 | 2019 | 23284 | 0.080 |
Why?
|
| Pharmacoepidemiology | 2 | 2019 | 291 | 0.080 |
Why?
|
| Boston | 4 | 2015 | 9402 | 0.080 |
Why?
|
| Versicans | 1 | 2007 | 30 | 0.080 |
Why?
|
| Retreatment | 1 | 2009 | 628 | 0.080 |
Why?
|
| Anthropometry | 2 | 2002 | 1367 | 0.080 |
Why?
|
| Linear Models | 3 | 2014 | 5986 | 0.080 |
Why?
|
| Area Under Curve | 2 | 2002 | 1688 | 0.080 |
Why?
|
| Quality of Life | 4 | 2006 | 11594 | 0.080 |
Why?
|
| Antidepressive Agents | 1 | 2019 | 2813 | 0.080 |
Why?
|
| Genetic Association Studies | 1 | 2016 | 2709 | 0.080 |
Why?
|
| Weight Gain | 2 | 2019 | 2193 | 0.080 |
Why?
|
| Seasons | 1 | 2012 | 1433 | 0.080 |
Why?
|
| Hyperparathyroidism, Primary | 1 | 2008 | 147 | 0.080 |
Why?
|
| Endocrinology | 1 | 2012 | 414 | 0.080 |
Why?
|
| Cyclic AMP | 1 | 2010 | 1530 | 0.080 |
Why?
|
| Body Constitution | 2 | 2004 | 275 | 0.070 |
Why?
|
| Exercise | 2 | 2022 | 5251 | 0.070 |
Why?
|
| Canada | 3 | 2015 | 1915 | 0.070 |
Why?
|
| Socioeconomic Factors | 2 | 2019 | 7644 | 0.070 |
Why?
|
| Serotonin Uptake Inhibitors | 1 | 2013 | 1419 | 0.070 |
Why?
|
| Aromatase | 1 | 2005 | 147 | 0.070 |
Why?
|
| Patient Care Team | 1 | 2017 | 2587 | 0.070 |
Why?
|
| Physicians, Family | 1 | 2007 | 357 | 0.070 |
Why?
|
| Drug Interactions | 1 | 2010 | 1456 | 0.070 |
Why?
|
| Bone Diseases | 1 | 2009 | 423 | 0.070 |
Why?
|
| Palliative Care | 4 | 2017 | 3261 | 0.070 |
Why?
|
| Chi-Square Distribution | 1 | 2012 | 3562 | 0.070 |
Why?
|
| Immunoglobulin G | 1 | 2017 | 4422 | 0.070 |
Why?
|
| Anorexia Nervosa | 1 | 2014 | 1317 | 0.070 |
Why?
|
| Osteoprotegerin | 1 | 2005 | 177 | 0.070 |
Why?
|
| Prostate-Specific Antigen | 3 | 2011 | 2245 | 0.070 |
Why?
|
| Pennsylvania | 4 | 2008 | 651 | 0.060 |
Why?
|
| Length of Stay | 2 | 2015 | 6257 | 0.060 |
Why?
|
| Tosyl Compounds | 1 | 2004 | 117 | 0.060 |
Why?
|
| Genetic Predisposition to Disease | 2 | 2016 | 17218 | 0.060 |
Why?
|
| Waist Circumference | 2 | 2021 | 895 | 0.060 |
Why?
|
| Phantoms, Imaging | 1 | 2012 | 2401 | 0.060 |
Why?
|
| Weight Loss | 1 | 2015 | 2450 | 0.060 |
Why?
|
| Pain | 3 | 2016 | 4636 | 0.060 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2010 | 3968 | 0.060 |
Why?
|
| Extravasation of Diagnostic and Therapeutic Materials | 1 | 2003 | 107 | 0.060 |
Why?
|
| Pregnanediol | 2 | 2017 | 17 | 0.060 |
Why?
|
| Control Groups | 1 | 2002 | 91 | 0.060 |
Why?
|
| Medicare | 2 | 2012 | 5691 | 0.060 |
Why?
|
| Androsterone | 2 | 2001 | 14 | 0.060 |
Why?
|
| Etiocholanolone | 2 | 2001 | 7 | 0.060 |
Why?
|
| Corpus Luteum | 2 | 2017 | 91 | 0.060 |
Why?
|
| Receptors, Tumor Necrosis Factor | 1 | 2005 | 616 | 0.060 |
Why?
|
| Estrogen Replacement Therapy | 2 | 2006 | 1178 | 0.060 |
Why?
|
| Patient Selection | 3 | 2015 | 4306 | 0.060 |
Why?
|
| Glucuronides | 1 | 2001 | 20 | 0.060 |
Why?
|
| Recovery of Function | 2 | 2014 | 2950 | 0.060 |
Why?
|
| Syndrome | 1 | 2008 | 3177 | 0.060 |
Why?
|
| Adiponectin | 1 | 2008 | 1081 | 0.050 |
Why?
|
| Calcifediol | 2 | 2015 | 171 | 0.050 |
Why?
|
| Hip Joint | 3 | 2014 | 932 | 0.050 |
Why?
|
| Antineoplastic Agents | 2 | 2004 | 13714 | 0.050 |
Why?
|
| Diabetes Mellitus, Type 1 | 1 | 2016 | 3354 | 0.050 |
Why?
|
| Pain Measurement | 2 | 2016 | 3510 | 0.050 |
Why?
|
| Guideline Adherence | 1 | 2012 | 2315 | 0.050 |
Why?
|
| Propylamines | 3 | 1966 | 164 | 0.050 |
Why?
|
| HIV Wasting Syndrome | 1 | 2001 | 101 | 0.050 |
Why?
|
| Sodium | 1 | 2006 | 1637 | 0.050 |
Why?
|
| Dihydrotestosterone | 1 | 2001 | 194 | 0.050 |
Why?
|
| Infusions, Intravenous | 3 | 2007 | 2303 | 0.050 |
Why?
|
| Drug Administration Schedule | 5 | 2007 | 5045 | 0.050 |
Why?
|
| Safety | 1 | 2006 | 1224 | 0.050 |
Why?
|
| Monoamine Oxidase Inhibitors | 3 | 1966 | 167 | 0.050 |
Why?
|
| Life Style | 2 | 2002 | 3636 | 0.050 |
Why?
|
| Ovariectomy | 1 | 2023 | 656 | 0.050 |
Why?
|
| Receptors, Cytoplasmic and Nuclear | 1 | 2005 | 860 | 0.050 |
Why?
|
| Biopsy, Needle | 1 | 2006 | 1682 | 0.050 |
Why?
|
| Disability Evaluation | 1 | 2008 | 1829 | 0.050 |
Why?
|
| Imidazoles | 1 | 2007 | 1268 | 0.050 |
Why?
|
| Occupational Diseases | 1 | 1988 | 1298 | 0.050 |
Why?
|
| Insulin | 1 | 2015 | 6648 | 0.050 |
Why?
|
| Calcium Gluconate | 1 | 1999 | 22 | 0.050 |
Why?
|
| Depressive Disorder | 1 | 2013 | 3811 | 0.050 |
Why?
|
| Family Practice | 1 | 2003 | 522 | 0.050 |
Why?
|
| New England | 1 | 2003 | 1021 | 0.050 |
Why?
|
| Evidence-Based Medicine | 1 | 2012 | 3690 | 0.050 |
Why?
|
| Pirenzepine | 1 | 1999 | 117 | 0.050 |
Why?
|
| Inpatients | 2 | 2022 | 2207 | 0.050 |
Why?
|
| Thoracic Vertebrae | 1 | 2004 | 613 | 0.050 |
Why?
|
| Phenotype | 2 | 2016 | 16306 | 0.040 |
Why?
|
| Severity of Illness Index | 4 | 2015 | 16008 | 0.040 |
Why?
|
| Joint Instability | 1 | 2006 | 748 | 0.040 |
Why?
|
| Blood Pressure | 3 | 2019 | 8528 | 0.040 |
Why?
|
| Data Interpretation, Statistical | 2 | 2006 | 2716 | 0.040 |
Why?
|
| Health Maintenance Organizations | 1 | 2001 | 669 | 0.040 |
Why?
|
| Calcium, Dietary | 1 | 2001 | 518 | 0.040 |
Why?
|
| Neoplasm Recurrence, Local | 2 | 2011 | 8877 | 0.040 |
Why?
|
| Hip Fractures | 1 | 2006 | 867 | 0.040 |
Why?
|
| Lipids | 2 | 2008 | 3246 | 0.040 |
Why?
|
| Drug Synergism | 1 | 2003 | 1875 | 0.040 |
Why?
|
| Incidence | 2 | 2015 | 20320 | 0.040 |
Why?
|
| Sexual Behavior, Animal | 1 | 1978 | 122 | 0.040 |
Why?
|
| Feedback | 2 | 1991 | 747 | 0.040 |
Why?
|
| Protein Precursors | 1 | 2002 | 1188 | 0.040 |
Why?
|
| Sodium Oxybate | 1 | 1997 | 22 | 0.040 |
Why?
|
| Pineal Gland | 1 | 1978 | 170 | 0.040 |
Why?
|
| Karnofsky Performance Status | 1 | 2017 | 186 | 0.040 |
Why?
|
| Diet Surveys | 1 | 2022 | 1157 | 0.040 |
Why?
|
| Medication Adherence | 1 | 2009 | 2019 | 0.040 |
Why?
|
| Attitude to Health | 1 | 2007 | 2102 | 0.040 |
Why?
|
| Referral and Consultation | 2 | 2017 | 3436 | 0.040 |
Why?
|
| Double-Blind Method | 3 | 2015 | 11877 | 0.040 |
Why?
|
| Aldehyde Oxidoreductases | 1 | 1997 | 91 | 0.040 |
Why?
|
| Fertility Agents, Female | 1 | 2017 | 96 | 0.040 |
Why?
|
| Sports | 1 | 2003 | 652 | 0.040 |
Why?
|
| Hysterectomy | 1 | 2023 | 902 | 0.040 |
Why?
|
| Diabetic Ketoacidosis | 1 | 1999 | 224 | 0.040 |
Why?
|
| Ontario | 1 | 2017 | 358 | 0.040 |
Why?
|
| Accidental Falls | 2 | 2019 | 1025 | 0.040 |
Why?
|
| Multicenter Studies as Topic | 1 | 2001 | 1513 | 0.040 |
Why?
|
| Glycoproteins | 1 | 2005 | 2309 | 0.040 |
Why?
|
| Intra-Abdominal Fat | 1 | 2021 | 578 | 0.040 |
Why?
|
| Sunlight | 1 | 1998 | 324 | 0.040 |
Why?
|
| C-Reactive Protein | 1 | 2008 | 3696 | 0.040 |
Why?
|
| Secondary Prevention | 1 | 2022 | 1505 | 0.040 |
Why?
|
| 25-Hydroxyvitamin D 2 | 1 | 2015 | 40 | 0.040 |
Why?
|
| Retrospective Studies | 8 | 2021 | 71483 | 0.040 |
Why?
|
| Estrogens, Conjugated (USP) | 1 | 2017 | 254 | 0.040 |
Why?
|
| Iproniazid | 2 | 1966 | 9 | 0.040 |
Why?
|
| Abbreviated Injury Scale | 1 | 2014 | 47 | 0.030 |
Why?
|
| Light | 2 | 1978 | 1418 | 0.030 |
Why?
|
| Amino Acids | 1 | 2001 | 1752 | 0.030 |
Why?
|
| Iodine Radioisotopes | 2 | 1989 | 1034 | 0.030 |
Why?
|
| Gonads | 1 | 2014 | 107 | 0.030 |
Why?
|
| Child | 4 | 2021 | 73636 | 0.030 |
Why?
|
| Radionuclide Imaging | 2 | 1989 | 2028 | 0.030 |
Why?
|
| Porosity | 1 | 2014 | 353 | 0.030 |
Why?
|
| Arthritis, Rheumatoid | 1 | 2009 | 3609 | 0.030 |
Why?
|
| Osteolysis | 2 | 2007 | 266 | 0.030 |
Why?
|
| Enzyme Inhibitors | 2 | 2003 | 3936 | 0.030 |
Why?
|
| Dehydroepiandrosterone Sulfate | 2 | 2005 | 234 | 0.030 |
Why?
|
| Health Services Research | 1 | 2001 | 1836 | 0.030 |
Why?
|
| Adenocarcinoma | 1 | 2011 | 6338 | 0.030 |
Why?
|
| Thyrotropin | 2 | 2003 | 820 | 0.030 |
Why?
|
| Mass Spectrometry | 1 | 2000 | 2244 | 0.030 |
Why?
|
| Self Efficacy | 2 | 2008 | 629 | 0.030 |
Why?
|
| Lymphatic Metastasis | 1 | 2001 | 2951 | 0.030 |
Why?
|
| Radioimmunoassay | 3 | 1989 | 954 | 0.030 |
Why?
|
| Testolactone | 1 | 1991 | 7 | 0.030 |
Why?
|
| Calibration | 1 | 1994 | 802 | 0.030 |
Why?
|
| Quinoxalines | 1 | 2014 | 298 | 0.030 |
Why?
|
| Diabetes Complications | 1 | 1999 | 1394 | 0.030 |
Why?
|
| Glucocorticoids | 2 | 2008 | 2125 | 0.030 |
Why?
|
| Pulmonary Embolism | 1 | 2004 | 2371 | 0.030 |
Why?
|
| Human Growth Hormone | 1 | 1996 | 699 | 0.030 |
Why?
|
| Respiratory Function Tests | 1 | 2015 | 1673 | 0.030 |
Why?
|
| Glycoprotein Hormones, alpha Subunit | 1 | 1990 | 97 | 0.030 |
Why?
|
| Breast Neoplasms | 3 | 2010 | 19800 | 0.030 |
Why?
|
| Women | 1 | 2012 | 224 | 0.020 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2005 | 3097 | 0.020 |
Why?
|
| Predictive Value of Tests | 3 | 2014 | 15252 | 0.020 |
Why?
|
| Medical Records | 1 | 1996 | 1410 | 0.020 |
Why?
|
| Iodobenzoates | 1 | 1989 | 11 | 0.020 |
Why?
|
| Insulin-Like Growth Factor I | 2 | 2014 | 2032 | 0.020 |
Why?
|
| Neurosecretory Systems | 1 | 1991 | 238 | 0.020 |
Why?
|
| Radiography | 2 | 2011 | 6989 | 0.020 |
Why?
|
| Triiodobenzoic Acids | 1 | 1989 | 119 | 0.020 |
Why?
|
| Analysis of Variance | 1 | 1998 | 6530 | 0.020 |
Why?
|
| Fracture Healing | 1 | 2011 | 405 | 0.020 |
Why?
|
| Age Distribution | 2 | 2005 | 2876 | 0.020 |
Why?
|
| Prevalence | 2 | 2012 | 14712 | 0.020 |
Why?
|
| Periodicity | 4 | 1990 | 377 | 0.020 |
Why?
|
| Viscera | 1 | 1989 | 149 | 0.020 |
Why?
|
| Gonadotropins, Pituitary | 1 | 1988 | 73 | 0.020 |
Why?
|
| Testis | 2 | 1989 | 813 | 0.020 |
Why?
|
| Algorithms | 1 | 2009 | 13647 | 0.020 |
Why?
|
| Fasting | 1 | 2014 | 1608 | 0.020 |
Why?
|
| Technetium Tc 99m Sestamibi | 1 | 2008 | 192 | 0.020 |
Why?
|
| Infusion Pumps | 1 | 1988 | 168 | 0.020 |
Why?
|
| Etidronic Acid | 1 | 2007 | 66 | 0.020 |
Why?
|
| Sleep | 2 | 2021 | 4143 | 0.020 |
Why?
|
| Parathyroid Neoplasms | 1 | 2008 | 243 | 0.020 |
Why?
|
| Isocarboxazid | 1 | 1966 | 8 | 0.020 |
Why?
|
| Tranylcypromine | 1 | 1966 | 36 | 0.020 |
Why?
|
| Primary Health Care | 1 | 2003 | 4485 | 0.020 |
Why?
|
| Neoplasm Metastasis | 1 | 2017 | 5112 | 0.020 |
Why?
|
| Antipsychotic Agents | 1 | 1999 | 3033 | 0.020 |
Why?
|
| Compressive Strength | 1 | 2006 | 162 | 0.020 |
Why?
|
| Injections, Intravenous | 1 | 1988 | 1472 | 0.020 |
Why?
|
| Calcitonin | 1 | 2007 | 352 | 0.020 |
Why?
|
| Body Height |